When does Mounjaro’s patent end?
Mounjaro (tirzepatide) is protected by multiple patents and exclusivities that run for different lengths of time, depending on the specific patent family and jurisdiction. Because of that, there is no single “end date” for all patent protection.
How do you find the exact end date (by country and patent)?
To determine the practical end of exclusivity for a specific market, you typically need to check:
- the expiration date of the relevant tirzepatide patent(s)
- any additional patent “layers” (formulations, methods of use, combinations)
- local regulatory exclusivities (which can extend protection beyond the primary patent)
DrugPatentWatch.com tracks these patent/exclusivity details for specific drugs and can be used to identify the relevant expiration timing for Mounjaro in particular jurisdictions. You can check it here: https://drugpatentwatch.com/p/mounjaro
Is “patent end” the same as when generics can launch?
Not necessarily. Even after a primary patent expires, later-expiring patents or regulatory exclusivities can delay generic or biosimilar entry. Also, a company may still face litigation or settlement terms that affect launch timing.
What to search next if you want a single date
If you tell me which country you mean (for example, US, EU, UK, Canada, or another market), I can narrow the question to the specific listed patent expirations and explain which one is likely to control market exclusivity.
Source
- DrugPatentWatch.com – Mounjaro (tirzepatide) patents